Discovery of a Novel Non-Nucleoside Inhibitor of RNA-Dependent RNA Polymerase Against Dengue Virus

Abstract

Dengue virus (DENV) is an acute infectious pathogen worldwide, for which no effective therapeutics are available. The RNA-dependent RNA polymerase (RdRp) displays an important role during DENV replication and is therefore a promising target in the development of antiviral drugs. However, there are still no clinically approved RdRp inhibitors available. In this study, we identified a natural small molecule, 12β-hydroxydammar-3-one-20(S)-O-β-d-glucopyranoside (PN-1), using a surface plasmon resonance-based screening assay. Biochemical and structural analyses revealed that PN-1 selectively targets the RdRp of DENV NS5 protein by covalently modifying residues Glu255, Met387, Glu479, and Ala507. Mechanistic studies involving tryptophan scanning and hydrogen-deuterium exchange mass spectrometry revealed that PN-1 binding regulates RdRp conformational transitions. This allosteric mechanism leads to suppression of enzymatic activity and inhibition of DENV replication. Consequently, PN-1 exhibited potent antiviral activity across various cell lines and conferred significant protection in both ICR suckling and AG129 mouse models. Taken together, our results show that PN-1 functions as a novel non-nucleoside inhibitor to suppress DENV replication by targeting RdRp. These findings highlight PN-1 as a promising anti-DENV lead compound, while revealing conserved RdRp residues as actionable targets for rational drug design.

Keywords

AG129 mice / dengue virus / ICR suckling / RNA-dependent RNA polymerase / target

References

[1] G. Paz-Bailey, L. E. Adams, J. Deen, et al., “Dengue,” Lancet 403 (2024): 667–682.

[2] C. P. Simmons, J. J. Farrar, V. V. Nguyen, and B. Wills, “Dengue,” New England Journal of Medicine 366 (2012): 1423–1432.

[3] J. D. Stanaway, D. S. Shepard, E. A. Undurraga, et al., “The Global Burden of Dengue: An Analysis From the Global Burden of Disease Study 2013,” Lancet Infectious Diseases 16, no. 6 (2016): 712–723.

[4] J. P. Messina, O. J. Brady, N. Golding, et al., “The Current and Future Global Distribution and Population at Risk of Dengue,” Nature Microbiology 4, no. 9 (2019): 1508–1515.

[5] World Health Organization, "Dengue and Severe Dengue," accessed April 23, 2024, https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.

[6] World Health Organization, "Global Dengue Surveillance," accessed May 18, 2025, https://worldhealthorg.shinyapps.io/dengue_global.

[7] T. M. Sharp, K. B. Anderson, L. C. Katzelnick, et al., “Knowledge Gaps in the Epidemiology of Severe Dengue Impede Vaccine Evaluation,” Lancet Infectious Diseases 22, no. 2 (2022): e42–e51.

[8] V. Tricou, D. Yu, H. Reynales, et al., “Long-Term Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003): 4·5-Year Results From a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial,” Lancet Global Health 12, no. 2 (2024): e257–e270.

[9] T. Osawa, M. Aoki, H. Ehara, and S. I. Sekine, “Structures of Dengue Virus RNA Replicase Complexes,” Molecular Cell 83, no. 15 (2023): 2781–2791.

[10] N. Uno and T. M. Ross, “Dengue Virus and the Host Innate Immune Response,” Emerging Microbes & Infections 7, no. 1 (2018): 167.

[11] V. J. Klema, M. Ye, A. Hindupur, et al., “Dengue Virus Nonstructural Protein 5 (NS5) Assembles Into a Dimer With a Unique Methyltransferase and Polymerase Interface,” PLoS Pathogen 12, no. 2 (2016): e1005451.

[12] S. P. Lim, C. G. Noble, C. C. Seh, et al., “Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance Profiling,” PLoS Pathogen 12, no. 8 (2016): e1005737.

[13] M. Ackermann and R. Padmanabhan, “De Novo Synthesis of RNA by the Dengue Virus RNA-dependent RNA Polymerase Exhibits Temperature Dependence at the Initiation but Not Elongation Phase,” Journal of Biological Chemistry 276, no. 43 (2001): 39926–39937.

[14] S. P. Lim, C. G. Noble, and P. Y. Shi, “The Dengue Virus NS5 Protein as a Target for Drug Discovery,” Antiviral Research 119 (2015): 57–67.

[15] D. S. Aschenbrenner, “Remdesivir Approved to Treat COVID-19 Amid Controversy,” American Journal of Nursing 121, no. 1 (2021): 22–24.

[16] E. De Clercq and G. Li, “Approved Antiviral Drugs Over the Past 50 Years,” Clinical Microbiology Reviews 29, no. 3 (2016): 695–747.

[17] A. A. Eltahla, F. Luciani, P. A. White, et al., “Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance,” Viruses 7, no. 10 (2015): 5206–5224.

[18] H. Malet, N. Massé, B. Selisko, et al., “The Flavivirus Polymerase as a Target for Drug Discovery,” Antiviral Research 80, no. 1 (2008): 23–35.

[19] G. P. Sreekanth, “Perspectives on the Current Antiviral Developments Towards RNA-Dependent RNA Polymerase (RdRp) and Methyltransferase (MTase) Domains of Dengue Virus Non-Structural Protein 5 (DENV-NS5),” European Journal of Medicinal Chemistry 256 (2023): 115416.

[20] Z. Yin, Y. L. Chen, W. Schul, et al., “An Adenosine Nucleoside Inhibitor of Dengue Virus,” Proceedings of the National Academy of Sciences 106, no. 48 (2009): 20435–20439.

[21] N. M. Nguyen, C. N. Tran, L. K. Phung, et al., “A Randomized, Double-blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients,” Journal of Infectious Diseases 207, no. 9 (2013): 1442–1450.

[22] M. Wang, H. Li, W. Liu, et al., “Dammarane-Type Leads Panaxadiol and Protopanaxadiol for Drug Discovery: Biological Activity and Structural Modification,” European Journal of Medicinal Chemistry 189 (2020): 112087.

[23] Y. Zhang, X. Zhong, Z. Xi, et al., “Antiviral Potential of the Genus Panax: An Updated Review on Their Effects and Underlying Mechanism of Action,” Journal of Ginseng Research 47, no. 2 (2023): 183–192.

[24] S. Wright and E. Altman, “Inhibition of Herpes Simplex Viruses, Types 1 and 2, by Ginsenoside 20(S)-Rg3,” Journal of Microbiology and Biotechnology 30, no. 1 (2020): 101–108.

[25] F. Oesch, B. Oesch-Bartlomowicz, and T. Efferth, “Toxicity as Prime Selection Criterion Among SARS-Active Herbal Medications,” Phytomedicine 85 (2021): 153476.

[26] J. G. Choi, Y. H. Jin, H. Lee, et al., “Protective Effect of Panax Notoginseng Root Water Extract Against Influenza A Virus Infection by Enhancing Antiviral Interferon-Mediated Immune Responses and Natural Killer Cell Activity,” Frontiers in Immunology 8 (2017): 1542.

[27] S. J. Kim, J. Y. Jang, E. J. Kim, et al., “Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation,” Hepatology 66, no. 3 (2017): 758–771.

[28] Y. R. Zheng, C. L. Fan, Y. Chen, et al., “Anti-Inflammatory, Anti-Angiogenetic and Antiviral Activities of Dammarane-Type Triterpenoid Saponins From the Roots of Panax notoginseng,” Food Function 13, no. 6 (2022): 3590–3602.

[29] T. Rattanaburee, M. Junking, A. Panya, et al., “Inhibition of Dengue Virus Production and Cytokine/Chemokine Expression by Ribavirin and Compound A,” Antiviral Research 124 (2015): 83–92.

[30] L. Zinzula and E. Tramontano, “Strategies of Highly Pathogenic RNA Viruses to Block dsRNA Detection by RIG-I-Like Receptors: Hide, Mask, Hit,” Antiviral Research 100, no. 3 (2013): 615–635.

[31] K. W. Chan, S. Watanabe, R. Kavishna, et al., “Animal Models for Studying Dengue Pathogenesis and Therapy,” Antiviral Research 123 (2015): 5–14.

[32] M. F. van den Broek, U. Müller, S. Huang, et al., “Immune Defence in Mice Lacking Type I and/or Type II Interferon Receptors,” Immunological Reviews 148 (1995): 5–18.

[33] B. E. Martina, P. Koraka, and A. D. Osterhaus, “Dengue Virus Pathogenesis: An Integrated View,” Clinical Microbiology Reviews 22, no. 4 (2009): 564–581.

[34] A. Wilder-Smith, E. E. Ooi, O. Horstick, and B. Wills, “Dengue,” Lancet 393, no. 10169 (2019): 350–363.

[35] O. Ackaert, F. Vanhoutte, N. Verpoorten, et al., “Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-Serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers,” Clinical Infectious Diseases 77, no. 6 (2023): 857–865.

[36] J. E. Fraser, S. Watanabe, C. Wang, et al., “A Nuclear Transport Inhibitor That Modulates the Unfolded Protein Response and Provides in Vivo Protection Against Lethal Dengue Virus Infection,” Journal of Infectious Diseases 210, no. 11 (2014): 1780–1791.

[37] B. Troost and J. M. Smit, “Recent Advances in Antiviral Drug Development Towards Dengue Virus,” Current Opinion in Virology 43 (2020): 9–21.

[38] A. M. Bifani, K. W. K. Chan, D. Borrenberghs, et al., “Therapeutics for Flaviviral Infections,” Antiviral Research 210 (2023): 105517.

[39] Y. L. Chen, F. Yokokawa, and P. Y. Shi, “The Search for Nucleoside/Nucleotide Analog Inhibitors of Dengue Virus,” Antiviral Research 122 (2015): 12–19.

[40] Y. L. Chen, N. Abdul Ghafar, R. Karuna, et al., “Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates balapiravir,” Journal of Virology 88, no. 3 (2014): 1740–1747.

[41] M. Y. Tay, K. Smith, I. H. Ng, et al., “The C-Terminal 18 Amino Acid Region of Dengue Virus NS5 Regulates Its Subcellular Localization and Contains a Conserved Arginine Residue Essential for Infectious Virus Production,” PLoS Pathogen 12, no. 9 (2016): e1005886.

[42] M. J. Pryor, S. M. Rawlinson, R. E. Butcher, et al., “Nuclear Localization of dengue Virus Nonstructural Protein 5 Through Its Importin Alpha/Beta-recognized Nuclear Localization Sequences Is Integral to Viral Infection,” Traffic 8, no. 7 (2007): 795–807.

[43] W. C. Chen, C. H. Huang, W. Liu, and J. C. Lee, “Sulforaphane Suppresses Dengue Virus Replication by Inhibition of Dengue Protease and Enhancement of Antiviral Interferon Response Through Nrf2-Mediated Heme Oxygenase-1 Induction,” Antiviral Research 207 (2022): 105400.

[44] X. He, Y. Zheng, C. Tian, et al., “Quassinoids From Eurycoma longifolia With Antiviral Activities by Inhibiting Dengue Virus Replication,” Phytomedicine 110 (2023): 154650.

[45] R. Jafari, H. Almqvist, H. Axelsson, et al., “The Cellular Thermal Shift Assay for Evaluating Drug Target Interactions in Cells,” Nature Protocols 9, no. 9 (2014): 2100–2122.

[46] B. Lomenick, R. Hao, and N. Jonai, “Target Identification Using Drug Affinity Responsive Target Stability (DARTS),” Proceedings of the National Academy of Sciences 106, no. 51 (2009): 21984–21989.

[47] A. Shevchenko, H. Tomas, J. Havlis, et al., “In-Gel Digestion for Mass Spectrometric Characterization of Proteins and Proteomes,” Nature Protocols 1, no. 6 (2006): 2856–2860.

[48] A. T. Kong, F. V. Leprevost, D. M. Avtonomov, et al., “MSFragger: Ultrafast and Comprehensive Peptide Identification in Mass Spectrometry-Based Proteomics,” Nature Methods 14, no. 5 (2017): 513–520.

[49] J. C. Lee, C. K. Tseng, Y. H. Wu, et al., “Characterization of the Activity of 2'-C-methylcytidine Against Dengue Virus Replication,” Antiviral Research 116 (2015): 1–9.

[50] Z. Lu, P. Xie, D. Zhang, et al., “3-Dehydroandrographolide Protects Against Lipopolysaccharide-Induced Inflammation Through the Cholinergic Anti-inflammatory Pathway,” Biochemical Pharmacology 158 (2018): 305–317.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.